Genedx Holdings CORP Form 4 insider transactions

Kevin Feeley, CFO of GeneDx Holdings Corp., sold 931 shares of Class A Common Stock on March 12, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

GeneDx Holdings CEO Katherine Stueland sold 2,618 shares of Class A Common Stock on March 12, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Kareem Saad, Chief Transformation Officer of GeneDx Holdings Corp., sold 897 shares of Class A Common Stock to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition of 2,462 Class A Common Stock units through the vesting of restricted stock units on March 9, 2024.

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition of 6,547 shares of Class A Common Stock and corresponding disposal of restricted stock units on March 9, 2024.

Kareem Saad, Chief Transformation Officer of GeneDx Holdings Corp., reports the vesting of restricted stock units.

Casdin Capital, a significant shareholder in GeneDx Holdings Corp., has increased its holdings through recent purchases of Class A Common Stock.

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.